Amphastar Pharmaceuticals (AMPH) Cash & Current Investments (2013 - 2026)
Amphastar Pharmaceuticals (AMPH) posted quarterly Cash & Current Investments of $171.1 million for Q1 2026, down 6.47% year-over-year from $183.0 million in Q1 2025, and little changed quarter-over-quarter from $170.4 million in Q4 2025.
Amphastar Pharmaceuticals (AMPH) Cash & Current Investments (2013 - 2026) Analysis & Trends
Amphastar Pharmaceuticals' Cash & Current Investments history runs 14 years deep, the most recent figure standing at $171.1 million for Q1 2026.
- In Q1 2026, Cash & Current Investments fell 6.47% year-over-year to $171.1 million; the TTM figure through Mar 2026 stood at $171.1 million (down 6.47% YoY), while the FY2025 annual figure was $170.4 million, up 10.79% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $171.1 million, roughly flat from $170.4 million in the prior quarter.
- The five-year high for Cash & Current Investments was $271.0 million in Q3 2023, with the low at $144.5 million in Q4 2023.
- The 5-year median for Cash & Current Investments is $172.8 million (2022), against an average of $181.3 million.
- The sharpest annual moves came in 2023 and 2024: Cash & Current Investments surged 69.99% in 2023, then slipped 29.04% in 2024.
- Amphastar Pharmaceuticals' Cash & Current Investments stood at $156.3 million in 2022, then retreated by 7.57% to $144.5 million in 2023, then gained by 6.45% to $153.8 million in 2024, then grew by 10.79% to $170.4 million in 2025, then gained by 0.43% to $171.1 million in 2026.
- Business Quant data shows AMPH's Cash & Current Investments at $171.1 million in Q1 2026, $170.4 million in Q4 2025, and $216.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 963.33 Mn |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 1.68 Bn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 5.80 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 2.66 Bn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 389.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 164.00 Mn |
| 10 | Amphastar Pharmaceuticals | 944.46 Mn | 654.33 Mn | 93.47 Mn | 290.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 290.12 Mn |
| Mar 31, 2026 | 171.14 Mn |
| Dec 31, 2025 | 170.41 Mn |
| Sep 30, 2025 | 216.47 Mn |
| Jun 30, 2025 | 189.89 Mn |
| Mar 31, 2025 | 182.98 Mn |
| Dec 31, 2024 | 153.81 Mn |
| Sep 30, 2024 | 192.32 Mn |
| Jun 30, 2024 | 189.85 Mn |
| Mar 31, 2024 | 201.38 Mn |
| Dec 31, 2023 | 144.50 Mn |
| Sep 30, 2023 | 271.04 Mn |
| Jun 30, 2023 | 150.80 Mn |
| Mar 31, 2023 | 192.89 Mn |
| Dec 31, 2022 | 156.33 Mn |
| Sep 30, 2022 | 159.44 Mn |
| Jun 30, 2022 | 166.36 Mn |
| Mar 31, 2022 | 172.83 Mn |
| Dec 31, 2021 | 126.55 Mn |
| Sep 30, 2021 | 106.81 Mn |